Veligrotug's mechanism of action in patients with thyroid eye disease has not been fully characterized. Veligrotug is a humanized IgG1 monoclonal antibody that binds to IGF-1R and inhibits IGF-1R signaling by blocking ligand-induced receptor autophosphorylation.
No formal pharmacodynamic studies have been conducted with veligrotug.
The pharmacokinetics (PK) of veligrotug were described by a two-compartment population PK model based on data from 298 patients with thyroid eye disease receiving 10 mg/kg veligrotug every 3 weeks in 4 clinical trials. Following this dose regimen, the geometric mean estimates for steady-state area under the concentration curve (AUC), peak (Cmax), and trough (Ctrough) concentrations of veligrotug were 3450 mcg∙day/mL, 363 mcg/mL, and 97.8 mcg/mL, respectively.
The population PK estimated mean central and peripheral volume of distribution of veligrotug were 2.80 L and 2.50 L, respectively.
The population PK estimated mean (% relative standard error) linear clearance of veligrotug was 0.216 (2.7) L/day with a corresponding half-life of approximately 18 days.
Metabolism of veligrotug has not been fully characterized. However, veligrotug is expected to undergo metabolism via proteolysis.
No clinically meaningful differences in the pharmacokinetics of veligrotug were observed following administration of veligrotug based on patient's age (20-79 years), sex (216 female and 82 male), race/ethnicity (224 White, 22 Black, and 13 Asian), or weight (41-161 kg). Neither renal nor hepatic impairment is expected to influence the pharmacokinetics of veligrotug.
No studies evaluating the drug interaction potential of veligrotug have been conducted.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.